Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.39)
# 2,527
Out of 4,959 analysts
24
Total ratings
52.94%
Success rate
10.79%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BWAY BrainsWay | Maintains: Outperform | $15 → $19 | $14.99 | +26.75% | 4 | Aug 14, 2025 | |
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $25.11 | +23.46% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $4.96 | +152.02% | 1 | Oct 25, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $2.02 | +197.03% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.18 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $15.85 | +57.73% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $240 | $3.64 | +6,493.41% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $14.98 | +433.91% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $7.06 | +225.78% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $2.13 | +1,026.76% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $2.18 | +91,643.12% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.32 | - | 1 | Sep 27, 2017 |
BrainsWay
Aug 14, 2025
Maintains: Outperform
Price Target: $15 → $19
Current: $14.99
Upside: +26.75%
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $25.11
Upside: +23.46%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $4.96
Upside: +152.02%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $2.02
Upside: +197.03%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.18
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $15.85
Upside: +57.73%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $240
Current: $3.64
Upside: +6,493.41%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $14.98
Upside: +433.91%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $7.06
Upside: +225.78%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $2.13
Upside: +1,026.76%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $2.18
Upside: +91,643.12%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.32
Upside: -